{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:11:14Z","timestamp":1765728674121,"version":"3.40.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Innovative Medicine Initiative","award":["IMI\/115006"],"award-info":[{"award-number":["IMI\/115006"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.atherosclerosis.2018.05.014","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T17:05:11Z","timestamp":1527267911000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes"],"prefix":"10.1016","volume":"274","author":[{"given":"Marco","family":"Colombo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen C.","family":"Looker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassam","family":"Farran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Agakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.Julia","family":"Brosnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-3643","authenticated-orcid":false,"given":"Paul","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shona","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul N.","family":"Durrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.John","family":"Betteridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"McKeigue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-3288","authenticated-orcid":false,"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.05.014_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.05.014_bib2","first-page":"360","article-title":"Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review","volume":"98","author":"van Dieren","year":"2012","journal-title":"Heart Br Card Soc."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2018.05.014_bib4","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.2337\/db09-0206","article-title":"ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan","volume":"58","author":"Hiukka","year":"2009","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.05.014_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacl.2015.05.002","article-title":"The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis","volume":"9","author":"Wyler von Ballmoos","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.05.014_bib6","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/ATVBAHA.117.309007","article-title":"Apolipoprotein C-III levels and incident coronary artery disease risk: the EPIC-norfolk prospective population study","volume":"37","author":"van Capelleveen","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.05.014_bib7","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00125-015-3535-6","article-title":"Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes","volume":"58","author":"Looker","year":"2015","journal-title":"Diabetologia"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2018.05.014_bib8","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/CIRCULATIONAHA.115.015744","article-title":"Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia","volume":"132","author":"Gerstein","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.05.014_bib9","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2017-00273","article-title":"ORIGIN trial investigators. Validation of the ORIGIN cardiovascular biomarker panel and the value of adding troponin I in dysglycemic people","author":"Gerstein","year":"2017","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"issue":"9435","key":"10.1016\/j.atherosclerosis.2018.05.014_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.05.014_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.05.014_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/hrt.2006.108167","article-title":"Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC)","volume":"93","author":"Woodward","year":"2007","journal-title":"Heart Br Card Soc."},{"key":"10.1016\/j.atherosclerosis.2018.05.014_bib14","unstructured":"V-plex human IL-15 Kit: mesoscale. Available from: https:\/\/www.mesoscale.com\/products\/k151rdd-1\/. Accessed June 30, 2016."},{"key":"10.1016\/j.atherosclerosis.2018.05.014_bib16","unstructured":"Elecsys NT-ProBNP: Roche Diagnostics. Available from: http:\/\/www.cobas.com\/home\/product\/clinical-and-immunochemistry-testing\/elecsys-nt-probnp-assay.html. Accessed June 30, 2016."},{"key":"10.1016\/j.atherosclerosis.2018.05.014_bib17","unstructured":"Elecsys troponin T high sensistive (TnT-Hs): Roche Diagnostics. Available from: http:\/\/www.cobas.com\/home\/product\/clinical-and-immunochemistry-testing\/elecsys-troponin-t-hs-tnt-hs.html. Accessed June 30, 2016."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2018.05.014_bib18","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/s00125-015-3586-8","article-title":"Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial","volume":"58","author":"Soedamah-Muthu","year":"2015","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.05.014_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1373\/clinchem.2008.111401","article-title":"Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"55","author":"Charlton-Menys","year":"2009","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.05.014_bib20","first-page":"393","article-title":"Contemporary model for cardiovascular risk prediction in people with type 2 diabetes","volume":"18","author":"Kengne","year":"2011","journal-title":"Eur J Cardiovasc Prev Rehabil Off J Eur Soc Cardiol Work Groups Epidemiol Prev Card Rehabil Exerc Physiol"},{"year":"2014","series-title":"R: a Language and Environment for Statistical Computing","author":"R Core Team","key":"10.1016\/j.atherosclerosis.2018.05.014_bib21"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.05.014_bib22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc15-2439","article-title":"Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the atherosclerosis risk in Communities study, multi-ethnic study of atherosclerosis, and jackson heart study","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.05.014_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2018.05.014_bib24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1373\/clinchem.2008.103234","article-title":"Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study","volume":"54","author":"Scheffer","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.05.014_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/aje\/kwx143","article-title":"Apolipoprotein C-III and high-density lipoprotein subspecies defined by apolipoprotein C-III in relation to diabetes risk","author":"Aroner","year":"2017","journal-title":"Am. J. Epidemiol."},{"issue":"5908","key":"10.1016\/j.atherosclerosis.2018.05.014_bib26","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A\u00a0null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2018.05.014_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11883-016-0614-1","article-title":"Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?","volume":"18","author":"Taskinen","year":"2016","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2018.05.014_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12944-015-0129-8","article-title":"The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it","volume":"14","author":"Xiong","year":"2015","journal-title":"Lipids Health Dis."},{"issue":"27","key":"10.1016\/j.atherosclerosis.2018.05.014_bib29","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1016\/S0021-9258(18)55263-7","article-title":"Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway","volume":"266","author":"Sehayek","year":"1991","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.05.014_bib30","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/s41598-017-02601-7","article-title":"ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.05.014_bib31","article-title":"Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease","volume":"1","author":"Jensen","year":"2012","journal-title":"J\u00a0Am Heart Assoc."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.05.014_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98045","article-title":"Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk","volume":"3","author":"Morton","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.05.014_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.ATV.0000249620.68705.0d","article-title":"Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation","volume":"27","author":"Kawakami","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2018.05.014_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2011.06.066","article-title":"Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases","volume":"157","author":"Battistoni","year":"2012","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.05.014_bib35","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.ahj.2015.09.010","article-title":"Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"170","author":"Daniels","year":"2015","journal-title":"Am. Heart J."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2018.05.014_bib36","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1161\/CIRCULATIONAHA.109.884866","article-title":"B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies","volume":"120","author":"Di Angelantonio","year":"2009","journal-title":"Circulation"},{"year":"2010","series-title":"Chronic Heart Failure Diagnosis","author":"NICE","key":"10.1016\/j.atherosclerosis.2018.05.014_bib37"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.05.014_bib38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/eurheartj\/ehs239","article-title":"N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS","volume":"34","author":"Welsh","year":"2013","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2018.05.014_bib39","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1161\/CIRCULATIONAHA.117.027272","article-title":"Multimodality strategy for cardiovascular risk assessment: performance in 2 population-based cohorts","volume":"135","author":"de Lemos","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.05.014_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1475-2840-10-71","article-title":"NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis","volume":"10","author":"Reinhard","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"issue":"23","key":"10.1016\/j.atherosclerosis.2018.05.014_bib41","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur. Heart J."},{"issue":"13","key":"10.1016\/j.atherosclerosis.2018.05.014_bib42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/CIRCULATIONAHA.110.005264","article-title":"Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study","volume":"123","author":"Saunders","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2018.05.014_bib43","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2337\/dc15-1760","article-title":"Natriuretic peptide and high-sensitivity troponin for cardiovascular risk prediction in diabetes: the atherosclerosis risk in Communities (ARIC) study","volume":"39","author":"Gori","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2018.05.014_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2337\/dc13-1165","article-title":"The relative and combined ability of high-sensitivity cardiac troponin T and","volume":"37","author":"Hillis","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2018.05.014_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000099","article-title":"Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events?","volume":"6","author":"Sattar","year":"2009","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2018.05.014_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034218","article-title":"Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2018.05.014_bib47","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1161\/01.CIR.103.7.947","article-title":"Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study","volume":"103","author":"Volpato","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2018.05.014_bib48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1464-5491.2002.00643.x","article-title":"Design of the collaborative AtoRvastatin diabetes study (CARDS) in patients with type 2 diabetes","volume":"19","author":"Colhoun","year":"2002","journal-title":"Diabet Med J Br Diabet Assoc."},{"issue":"15","key":"10.1016\/j.atherosclerosis.2018.05.014_bib49","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"(NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018302569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018302569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:15:20Z","timestamp":1717200920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018302569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":46,"alternative-id":["S0021915018302569"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.05.014","relation":{},"ISSN":["0021-9150"],"issn-type":[{"type":"print","value":"0021-9150"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}